Gastroesophageal reflux disease
Conditions
Interventions
Experimental group:Tongyang Xuanbi pilulas combined with rabeprazole capsules
Control group:Tongyang Xuanbi pilulas placebo combined with rabeprazole capsules
Sponsors
Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria of chest pain associated with gastroesophageal reflux disease (electronic gastroscopy within 6 months before enrollment); 2. TCM syndrome differentiation of patients belongs to hypofunction of Yang Qi in chest; 3. Patients who had not taken medicine for this disease,such as acid suppressants or gastrointestinal motility drugs 2 weeks before enrollment; 4. Aged 18 to 70 years, regardless of gender; 5. Patients who understand and agree to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Chest pain caused by other noncardiac causes (chest wall disease, respiratory disease, mediastinal disease, psycho-psychiatric factors and other primary esophageal dynamic diseases such as achalasia from cardia, diffuse esophageal spasm, nutcracker esophagus, lower esophageal sphincter hypertension, etc.); 2.Gastroscopy results indicated patients have one of the following diseases: peptic ulcer, history of gastroesophageal and duodenal surgery, Zollinger-Ellison syndrome, pyloric obstruction,scleroderma,drug esophagitis, fungal esophagitis, gastrointestinal malignancy; 3.Patients with serious primary diseases of heart, brain, liver, lung, kidney, blood and endocrine system, which have not been effectively controlled, and patients with severe mental illness; 4.Patients who cannot take medication during pregnancy preparation, pregnancy or lactation; 5.Allergic to rabeprazole or any of the ingredients in Traditional Chinese medicine used in this study; 6.Patients who have participated in or are participating in other clinical trials 1 month before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Symptom Score;Visual Analogue Scale, VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Global Pain Scale, GPS;Brief Pain Inventory short form;Medical Outcomes Study SF-36 Questionnaire;Electronic Gastroscopy; | — |
Countries
China
Contacts
Public ContactZhou Bingduo
Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed